GHD Stock Overview
A biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Brainstorm Cell Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.69 |
| 52 Week High | US$12.03 |
| 52 Week Low | US$2.28 |
| Beta | 0.39 |
| 11 Month Change | 0% |
| 3 Month Change | -35.54% |
| 1 Year Change | -34.12% |
| 33 Year Change | -94.47% |
| 5 Year Change | -94.94% |
| Change since IPO | -97.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| GHD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | 1.1% |
| 1Y | -34.1% | -18.8% | 7.2% |
Return vs Industry: GHD underperformed the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: GHD underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| GHD volatility | |
|---|---|
| GHD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GHD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine GHD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 29 | Chaim Lebovits | www.brainstorm-cell.com |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases.
Brainstorm Cell Therapeutics Inc. Fundamentals Summary
| GHD fundamental statistics | |
|---|---|
| Market cap | €9.39m |
| Earnings (TTM) | -€13.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs GHD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GHD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.23m |
| Earnings | -US$14.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GHD perform over the long term?
See historical performance and comparison